Immunotherapy treatment accessible to cancer patients with a rare tumour profile


Oncologists, pharmaceutical manufacturers, health insurers and the Healthcare Institute together want to ensure that patients with a rare molecular tumour profile can gain access to cancer medicines that prove to be beneficial in a clinical study, although those medicines have not been developed for their cancer type.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.